We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: NIKE, Walgreens Boots Alliance, UnitedHealth, Pfizer and Home Depot
Read MoreHide Full Article
For Immediate Release
Chicago, IL – July 1, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: NIKE, Inc. (NKE - Free Report) , Walgreens Boots Alliance, Inc. (WBA - Free Report) , UnitedHealth Group, Inc. (UNH - Free Report) , Pfizer Inc. (PFE - Free Report) and The Home Depot, Inc. (HD - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Dow 30 Stock Roundup: NKE, WBA, UNH & More
The index suffered a disappointing week, declining over three straight trading sessions. Investors remained wary ahead of a crucial meeting between Presidents Trump and Xi at the G-20 summit in Japan. Investor sentiment was further dampened after Fed Chair Jerome Powell indicated that the central bank is yet to decide on whether a rate cut should take place in July.
Last Week’s Performance
The index gained 8.41 points on Monday as investors waited for a crucial meeting between Presidents Trump and Xi this week. Moreover, the Iranian crisis intensified as U.S. government imposed fresh sanctions on the oil-rich country. Consequently, gold prices soared as investors shifted to safe-haven precious metals.
The index moved down 0.7% on Tuesday after Powell stated that the central bank remained undecided about reducing the benchmark interest rate. The Dow dipped 179 points to post its worst single-day drop since May 31. Powell stated that the Fed was carefully monitoring the economy in order to avoid lowering interest rates in haste.
The index lost 0.04% on Wednesday as investors remained uncertain of a positive outcome to the G-20 summit. Initial optimism over a near-term trade deal faded after Trump suggested that would be happy to collect tariffs from China if the countries are unable to reach an agreement.
The Dow slipped 10.24 points, or less than 0.1%, marking its third consecutive decline. This is its longest stretch of losses since the five-session decline ended Mar 8. In doing so, it moved against broader markets, which were boosted by bank stocks which gained ahead of the release of Fed stress test results.
Components Moving the Index
NIKE, Inc. reported quarterly earnings of 62 cents per share, missing the Zacks Consensus Estimate of 66 cents. This compares to earnings of 69 cents per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents a negative earnings surprise of 6.06%. A quarter ago, it was expected that this athletic apparel maker would post earnings of 63 cents per share when it actually produced earnings of 68 cents, delivering a positive surprise of 7.94%. This is the first time in four quarters that the company has missed the consensus mark for earnings.
Zacks Rank #3 (Hold) Nike posted revenues of $10.18 billion for the quarter ended May 2019, surpassing the Zacks Consensus Estimate by 0.29%. This compares to year-ago revenues of $9.79 billion. The company has topped revenue estimates over each of the last four quarters. (Read: Nike Misses Q4 Earnings Estimates)
Walgreens Boots Alliance, Inc. reported adjusted earnings per share of $1.47 for third-quarter fiscal 2019, down 3.9% year over year (down 2.4% at constant exchange rate or CER). However, the figure exceeded the Zacks Consensus Estimate by 3.5%.
On a reported basis, net earnings came in at $1 billion, reflecting a 23.6% decline from the prior-year quarter. Reported earnings came in at $1.13, down 16.2% on a year-over-year basis.
This Zacks Rank #4 (Sell) company recorded total sales of $34.59 billion in the third quarter, up 0.7% year over year and 2.9% at constant exchange rate or CER. The top line edged past the Zacks Consensus Estimate of $34.53 billion. Gross profit in the reported quarter fell 4.2% year over year to $7.45 billion. However, gross margin contracted 111 basis points to 21.5%. (Read: Walgreens Boots Q3 Earnings Top Estimates, Margins Dip)
UnitedHealth Group, Inc. might buy the healthcare payments company Equian for nearly $3.2 billion, per multiple sources.
Equian delivers payment integrity solutions through proprietary content, enabling technology and highly responsive customer service. The company analyzes healthcare and insurance data to ensure that payments are fair, accurate, and paid by the correct party — resulting in billions of dollars of savings.
This buyout will allow Zacks Rank #3 UnitedHealth to add a new niche business to its health services segment, Optum, which deals in health management and engagement, health financial services, health IT, benefit operations, care operations and pharmacy care services. Over the years, Optum has grown to contribute an increasing proportion of total revenues. (Read: UnitedHealth to Buy Equian & Foray into Healthcare Payments)
Pfizer Inc. announced that the European Commission has approved its PARP inhibitor, Talzenna (talazoparib) for BRCA-mutated advanced breast cancer in previously-treated patients.
The drug is approved as monotherapy for treating locally advanced or metastatic breast cancer patients with HER2 negative, germline breast cancer susceptibility gene (gBRCA)1/2-mutations. Patients must have received prior treatment with an anthracycline and/or a taxane in the (neo) adjuvant setting or they should be ineligible for treatment with anthracycline/ taxane.
The drug is also approved for use in patients with HR+ breast cancer who have received prior endocrine-based therapy or are unsuitable for endocrine-based therapy. The stock has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Home Depot, Inc.posted first-quarter fiscal 2019 earnings of $2.27 per share, up 9.1% from $2.08 registered a year ago. The bottom line also beat the Zacks Consensus Estimate of $2.16. Home Depot has a Zacks Rank #3.
Net sales grew 5.7% to $26,381 million from $24,947 million in the year-ago quarter and surpassed the Zacks Consensus Estimate of $26,298 million. While the company's overall comps increased 2.5%, comps grew 3% in the United States. (Read: Home Depot Earnings & Sales Surpass Estimates in Q1)
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: NIKE, Walgreens Boots Alliance, UnitedHealth, Pfizer and Home Depot
For Immediate Release
Chicago, IL – July 1, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: NIKE, Inc. (NKE - Free Report) , Walgreens Boots Alliance, Inc. (WBA - Free Report) , UnitedHealth Group, Inc. (UNH - Free Report) , Pfizer Inc. (PFE - Free Report) and The Home Depot, Inc. (HD - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Dow 30 Stock Roundup: NKE, WBA, UNH & More
The index suffered a disappointing week, declining over three straight trading sessions. Investors remained wary ahead of a crucial meeting between Presidents Trump and Xi at the G-20 summit in Japan. Investor sentiment was further dampened after Fed Chair Jerome Powell indicated that the central bank is yet to decide on whether a rate cut should take place in July.
Last Week’s Performance
The index gained 8.41 points on Monday as investors waited for a crucial meeting between Presidents Trump and Xi this week. Moreover, the Iranian crisis intensified as U.S. government imposed fresh sanctions on the oil-rich country. Consequently, gold prices soared as investors shifted to safe-haven precious metals.
The index moved down 0.7% on Tuesday after Powell stated that the central bank remained undecided about reducing the benchmark interest rate. The Dow dipped 179 points to post its worst single-day drop since May 31. Powell stated that the Fed was carefully monitoring the economy in order to avoid lowering interest rates in haste.
The index lost 0.04% on Wednesday as investors remained uncertain of a positive outcome to the G-20 summit. Initial optimism over a near-term trade deal faded after Trump suggested that would be happy to collect tariffs from China if the countries are unable to reach an agreement.
The Dow slipped 10.24 points, or less than 0.1%, marking its third consecutive decline. This is its longest stretch of losses since the five-session decline ended Mar 8. In doing so, it moved against broader markets, which were boosted by bank stocks which gained ahead of the release of Fed stress test results.
Components Moving the Index
NIKE, Inc. reported quarterly earnings of 62 cents per share, missing the Zacks Consensus Estimate of 66 cents. This compares to earnings of 69 cents per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents a negative earnings surprise of 6.06%. A quarter ago, it was expected that this athletic apparel maker would post earnings of 63 cents per share when it actually produced earnings of 68 cents, delivering a positive surprise of 7.94%. This is the first time in four quarters that the company has missed the consensus mark for earnings.
Zacks Rank #3 (Hold) Nike posted revenues of $10.18 billion for the quarter ended May 2019, surpassing the Zacks Consensus Estimate by 0.29%. This compares to year-ago revenues of $9.79 billion. The company has topped revenue estimates over each of the last four quarters. (Read: Nike Misses Q4 Earnings Estimates)
Walgreens Boots Alliance, Inc. reported adjusted earnings per share of $1.47 for third-quarter fiscal 2019, down 3.9% year over year (down 2.4% at constant exchange rate or CER). However, the figure exceeded the Zacks Consensus Estimate by 3.5%.
On a reported basis, net earnings came in at $1 billion, reflecting a 23.6% decline from the prior-year quarter. Reported earnings came in at $1.13, down 16.2% on a year-over-year basis.
This Zacks Rank #4 (Sell) company recorded total sales of $34.59 billion in the third quarter, up 0.7% year over year and 2.9% at constant exchange rate or CER. The top line edged past the Zacks Consensus Estimate of $34.53 billion. Gross profit in the reported quarter fell 4.2% year over year to $7.45 billion. However, gross margin contracted 111 basis points to 21.5%. (Read: Walgreens Boots Q3 Earnings Top Estimates, Margins Dip)
UnitedHealth Group, Inc. might buy the healthcare payments company Equian for nearly $3.2 billion, per multiple sources.
Equian delivers payment integrity solutions through proprietary content, enabling technology and highly responsive customer service. The company analyzes healthcare and insurance data to ensure that payments are fair, accurate, and paid by the correct party — resulting in billions of dollars of savings.
This buyout will allow Zacks Rank #3 UnitedHealth to add a new niche business to its health services segment, Optum, which deals in health management and engagement, health financial services, health IT, benefit operations, care operations and pharmacy care services. Over the years, Optum has grown to contribute an increasing proportion of total revenues. (Read: UnitedHealth to Buy Equian & Foray into Healthcare Payments)
Pfizer Inc. announced that the European Commission has approved its PARP inhibitor, Talzenna (talazoparib) for BRCA-mutated advanced breast cancer in previously-treated patients.
The drug is approved as monotherapy for treating locally advanced or metastatic breast cancer patients with HER2 negative, germline breast cancer susceptibility gene (gBRCA)1/2-mutations. Patients must have received prior treatment with an anthracycline and/or a taxane in the (neo) adjuvant setting or they should be ineligible for treatment with anthracycline/ taxane.
The drug is also approved for use in patients with HR+ breast cancer who have received prior endocrine-based therapy or are unsuitable for endocrine-based therapy. The stock has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Home Depot, Inc.posted first-quarter fiscal 2019 earnings of $2.27 per share, up 9.1% from $2.08 registered a year ago. The bottom line also beat the Zacks Consensus Estimate of $2.16. Home Depot has a Zacks Rank #3.
Net sales grew 5.7% to $26,381 million from $24,947 million in the year-ago quarter and surpassed the Zacks Consensus Estimate of $26,298 million. While the company's overall comps increased 2.5%, comps grew 3% in the United States. (Read: Home Depot Earnings & Sales Surpass Estimates in Q1)
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.